Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Molecular Signatures in Inflammatory Skin Disease

Systematic Profiling of Anti-cytokine Signatures in the Treatment of Chronic Inflammatory Skin Disorders

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This pilot project intends to examine the utility of a systems medicine approach to identify regulatory networks and their perturbation in psoriasis and atopic dermatitis, and to obtain a comprehensive perspective on disease and disease control by integrating and modelling data across multiple cellular levels and time following specific blockade of single pathophysiological factors through use of licensed biologics during routine care as systems biology challenge. To this end, ultra-deep phenotyping and prospective molecular characterization in short time-intervals and different disease equilibrium states will be carried out in targeted small sets of patients. The different layers and types of clinical and molecular information will then be integrated (integrative personal omics profiling iPOP) for generating insights into disease pathways and for extraction of molecular signatures that correspond to clinical severity scores. It will provide a good starting point for planning future trials aimed at identifying biological patterns useful for guiding targeted treatment.

Who May Be Eligible (Plain English)

Who May Qualify: - Ability to provide written willing to sign a consent form and comply with the protocol - Dermatologist-diagnosed chronic inflammatory skin disease - Subject receives systemic therapy within routine care (in-label use of biologics) Who Should NOT Join This Trial: - Subject is unable to provide written willing to sign a consent form or comply with the protocol. - Having used immunosuppressive/immunomodulating therapy or phototherapy within 4 weeks before the baseline visit. - Treatment of selected skin areas to be examined with topical corticosteroid or topical calcineurin inhibitor within 1 week before the baseline visit. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Ability to provide written informed consent and comply with the protocol * Dermatologist-diagnosed chronic inflammatory skin disease * Subject receives systemic therapy within routine care (in-label use of biologics) Exclusion Criteria: * Subject is unable to provide written informed consent or comply with the protocol. * Having used immunosuppressive/immunomodulating therapy or phototherapy within 4 weeks before the baseline visit. * Treatment of selected skin areas to be examined with topical corticosteroid or topical calcineurin inhibitor within 1 week before the baseline visit.

Treatments Being Tested

DRUG

Anti-TNF

Subject receives anti-TNF antibodies open-label as per guidelines

DRUG

Anti-IL12/23

Subject receives anti-IL12/23 antibodies open-label as per guidelines

DRUG

Anti-IL17

Subject receives anti-IL17 antibodies open-label as per guidelines

DRUG

Dupilumab

Subject receives Dupilumab open-label as per guidelines

DRUG

Anti-IL23

Subject receives anti-IL23 antibodies open-label as per guidelines

DRUG

Baricitinib

Subject receives Baricitinib open-label as per guidelines

DRUG

Abrocitinib

Subject receives Abrocitinib open-label as per guidelines

DRUG

Upadacitinib

Subject receives Upadacitinib open-label as per guidelines

DRUG

Tralokinumab

Subject receives Tralokinumab open-label as per guidelines

DRUG

Lebrikizumab

Subject receives Lebrikizumab open-label as per guidelines

DRUG

Nemolizumab

Subject receives Nemolizumab open-label as per guidelines

Locations (1)

Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel
Kiel, Germany